impaired immunity in dlbcl survivors
Published 5 years ago • 1.5K plays • Length 3:04Download video MP4
Download video MP3
Similar videos
-
1:53
the current immunotherapeutic landscape for treatment of dlbcl
-
3:04
applying molecular understanding of dlbcl to management strategies
-
3:58
phase ib/iia study of azd4573 acalabrutinib in r/r dlbcl
-
2:38
immune landscape and responses to immune checkpoint blockade in lymphoma
-
1:04
immunotherapies in the future treatment landscape for waldenström's macroglobulinemia
-
2:33
the role of bispecific antibodies in the treatment of patients with multiple myeloma
-
2:39
advancements in bispecific and trispecific antibodies for the treatment of lymphoma
-
3:35
a trial investigating the addition of blinatumomab to consolidation chemotherapy in ph- all
-
1:51
sub-typing waldenström's macroglobulinemia: memory b-cell subtype and plasma cell-like subtype
-
5:15
the promise of immunotherapies in t-cell lymphoma
-
1:54
the modified risk stratification of wm: integrating older age, abnormal ldh, and low albumin
-
2:39
new findings and challenges in the use of immunotherapy in hodgkin lymphoma
-
3:09
novel strategies emerging for elderly patients with dlbcl and ongoing trials in this space
-
1:04
the effect of clonal hematopoiesis on treatment strategies for waldenström's macroglobulinemia
-
1:00
phase ib trial of r-chop plus iberdomide or golcadomide in aggressive b-cell lymphoma
-
1:06
epcore nhl-1: two and a half year follow-up of epcoritamab in dlbcl
-
1:21
novel approaches to harnessing the immune system in lymphoma
-
1:59
novel targets and therapeutics being explored in waldenström's macroglobulinemia
-
1:21
the role of transplant in the era of new treatments for lymphoma and cll
-
2:15
hovon/llpc transplant brave: novel salvage chemotherapy for r/r hodgkin lymphoma
-
1:01
pitfalls in the diagnosis of lymphoid malignancies: interpreting pet scans
-
2:01
tirabrutinib, a second-generation btki, in the treatment of symptomatic wm and bing-neel syndrome